Home › Funds › Tetragon Partners GP Ltd › ARWR

Tetragon Partners GP Ltd position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

Tetragon Partners GP Ltd reported holding 130,484 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$10.6M, representing 1.73% of its reported portfolio and ranking #12 among its reported holdings. Tetragon Partners GP Ltd has disclosed ARWR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)130.48K sh
Reported value held$10.64M
Portfolio Weight1.73%
First reportedQ3 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's ARWR position evolved

Tetragon Partners GP Ltd first disclosed a stake in ARWR in Q3 2025 at 81,841 shares (US$2.8M). The position peaked in Q2 2026 at 130,484 shares, worth US$10.6M. Across 4 filings, Tetragon Partners GP Ltd increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 130,484 shares valued at US$10.6M — an increase of 3,286 shares quarter over quarter.. Notable position changes include a 31% increase in Q1 2026 (shares rose 30% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 81.84K $2.82M New
Q4 2025 96.94K $6.44M Add
Q1 2026 127.20K $7.98M Add
Q2 2026 130.48K $10.64M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has Tetragon Partners GP Ltd held ARWR?

Tetragon Partners GP Ltd has disclosed ARWR holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Tetragon Partners GP Ltd's current position in ARWR?

As of Q2 2026, Tetragon Partners GP Ltd holds 130.48K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $10.64M, representing 1.73% of its reported portfolio and ranking #12.

Has Tetragon Partners GP Ltd been buying or selling ARWR?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in ARWR. The position peaked in Q2 2026 at 130.48K shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.